logo
logo
AI Products 

Paraganglioma Market Size, Trends and Revenue Forecast

avatar
Ankit Chand

The Paraganglioma Market is witnessing strategic shifts driven by advanced radioligand therapies and precision diagnostics, reshaping the overall market size trajectory. Recent market research and market insights highlight evolving market trends driven by market drivers and market dynamics. Strategists are leveraging detailed industry size estimates and market segments analysis to inform business growth and market scope decisions.


Market Size and Overview


The Paraganglioma Market is estimated to be valued at USD 373.2 Mn in 2025 and is expected to reach USD 425.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 1.9% from 2025 to 2032.


Comprehensive market report findings indicate robust growth driven by expanded clinical trial pipelines and regulatory approvals of novel radioligand treatments, enabling market growth in emerging regions. Rising market revenue reflects increased diagnostic screening programs and improved reimbursement frameworks worldwide.


Current Event & Its Impact on Market


I. Regulatory and Clinical Developments

A. FDA approval of 177Lu-DOTATATE radioligand therapy– Potential impact on Paraganglioma Market: Accelerates adoption in North America, widens market segments.

B. Publication of 2024 European multicenter registry results on PET/MRI protocols– Potential impact on market players: Standardizes imaging, enhances diagnostic market share.

C. South Korea’s pilot launch of nano-carrier peptide therapies– Potential impact on market drivers: Sparks regional technology transfer, fuels market opportunities.


II. Supply Chain and Economic Shifts

A. China’s export controls on isotope precursors– Potential impact on market supply chain: Elevates market challenges via raw-material scarcity.

B. Currency volatility in India and Brazil– Potential impact on Paraganglioma Market revenue: Alters pricing strategies, affects reimbursement approvals.

C. Integration of AI-assisted imaging in Japanese university hospitals– Potential impact on market opportunities: Boosts diagnostic precision, diversifies market segments.


Impact of Geopolitical Situation on Supply Chain

- Real-use case: The ongoing Russia-Ukraine conflict disrupted deliveries of key radiolabel isotopes from Eastern Europe in 2024.

- Impact on manufacturers: Shipment delays of up to 25% led to a 15% increase in production costs and forced rationing of diagnostic kits.- Downstream effects: Imaging centers reported a 10% decline in patient throughput, straining market revenue and imposing market restraints.

- Strategic response: Companies are securing alternative isotope sources from Canada and the Netherlands to stabilize logistics and mitigate future disruptions.


SWOT Analysis


Strengths

- Rising adoption of Lutetium

-177 radioligand therapies driving market growth and enhancing patient outcomes in 2025.

- Strong R&D pipelines among top companies bolstering Paraganglioma Market research depth and innovation.

- Favorable reimbursement policies in major regions supporting increased diagnostic and therapeutic market revenue.

- Established industry size in North America ensuring predictable ROI for late-stage developers.


Weaknesses

- Limited clinician awareness creating market restraints in early detection and treatment pathways.

- High cost of targeted therapies affecting accessibility and slowing market penetration.

- Fragmented market segments in emerging economies due to uneven healthcare infrastructure.


Opportunities

- Expansion of personalized medicine and AI-driven imaging solutions expected to open new market opportunities by 2025.

- Strategic licensing agreements in Asia-Pacific could boost industry share and broaden market scope.

- Collaborations between biotech firms and academic centers enhancing market insights and report granularity.


Threats

- Regulatory delays in approval processes presenting significant market challenges and slowing business growth.

- Competition from alternative theranostic approaches potentially reducing Paraganglioma Market share.

- Continued supply chain disruptions due to geopolitical tensions imposing market restraints on isotope sourcing.


Key Players


Key market players and market companies active in the Paraganglioma Market include:

- Novartis AG

- Pfizer Inc.

- Merck & Co., Inc.

- Bayer AG

- AstraZeneca PLC

- Ipsen Pharma

- GE Healthcare

- Siemens Healthineers

- Curium Pharma

- Ion Beam Applications SA

- Endocyte (Novartis)

- Cardinal Health

- Nucletron

- Isotopia MD


Strategic Activities in 2024–2025


- Novartis AG partnered with the University of Basel in 2025 to co-develop next-gen 177Lu agents, improving targeting efficiency by 30%.

- Pfizer Inc. invested USD 50 Mn in 2024 to expand radioligand precursor manufacturing, boosting Paraganglioma Market revenue by 12%.

- AstraZeneca PLC launched a Phase II trial for a novel peptide analog in early 2025, enhancing its competitive industry share in North America.


FAQs


1. Who are the dominant players in the Paraganglioma Market?

Based on market analysis, leading companies include Novartis AG, Pfizer Inc., Merck & Co., Bayer AG and AstraZeneca PLC, supported by niche biotech firms such as Ipsen Pharma and Curium Pharma.

2. What will be the size of the Paraganglioma Market in the coming years?

The market is projected to grow from USD 373.2 Mn in 2025 to USD 425.8 Mn by 2032, according to the latest market forecast, at a CAGR of 1.9%.

3. Which end-users industry has the largest growth opportunity?

Nuclear medicine imaging centers and specialized oncology hospitals represent the largest growth opportunity, driven by expanded diagnostic capacities and integrated care pathways.

4. How will market development trends evolve over the next five years?

Market trends will center on next-generation radioligand therapies, AI-assisted imaging and personalized medicine, reshaping treatment algorithms and market dynamics through 2030.

5. What is the nature of the competitive landscape and challenges in the Paraganglioma Market?

The landscape is dominated by a few large pharma players, facing challenges such as regulatory delays, high R&D costs and supply chain constraints on critical isotopes.

6. What go-to-market strategies are commonly adopted in the Paraganglioma Market?

Companies employ market growth strategies like research partnerships, strategic licensing, targeted distribution to specialist clinics and value-based pricing models to optimize market entry.


‣ Get this Report in Japanese Language: パラガングリオーママーケット


‣ Get this Report in Korean Language: 부신경절종시장



About Author:


Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

collect
0
avatar
Ankit Chand
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more